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Background: Many breast cancer patients use some form of dietary supplement (DS) to 
  complement their conventional cancer treatment, in the hope that they might lessen the side 
effects of treatment, improve quality of life, give a greater sense of control, and reduce stress. 
This pilot study assessed the level of DS usage by breast cancer patients undergoing conventional 
cancer treatment, and their concerns about the use of DS.
Method: A cross-sectional descriptive survey in three breast cancer centers in Hong Kong 
using face-to-face interviewing was performed.
Results: Of 82 female Chinese breast cancer patients who completed the survey, 99% reported 
that they had been using DS since their cancer was diagnosed. The most frequently used DS 
were Chinese herbal medicines, and patients spent about US$258 on DS every month. The 
reason given for using DS was to enhance their recovery from cancer, but at the same time the 
patients had safety concerns. However, most patients did not feel able to discuss these concerns 
with health professionals.
Conclusion: The majority of the patients had some safety concerns, and said that they would 
welcome detailed and reliable information on DS. The lack of reliable information on the 
  potential risks and benefits of using such supplements as an adjuvant to conventional treatment 
and the reluctance of patients to discuss their use of DS with health professionals is a major 
area of concern that warrants further attention.
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Introduction
Breast cancer is the most common malignancy diagnosed in women across the world 
today.1 Treatment options for breast cancer patients include surgery, radiotherapy, che-
motherapy, and hormone replacement therapy. Such treatments are aimed at   limiting the 
spread of cancerous cells in the body and containing the damage they inflict. Although 
advanced cancer treatments have marginally increased the survival rate of patients with 
breast cancer during the past decade, they often produce unpleasant complications.2 As 
a result, the experience of suffering from cancer is often a dreadful ordeal for patients, 
even for those who survive the disease. Besides coming to terms with the diagnosis 
of a life-threatening disease, many cancer patients are exposed to the unpleasant side 
effects of the treatment they receive, including fatigue, anxiety, menopausal symptoms, 
nausea, lymphedema, and dermatitis. These complications are side effects of life-saving 
therapies, can impair patients’ vitality and lower their quality of life, and are often very 
difficult to adjust to psychologically.3 Many breast cancer patients therefore use some 
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cancer treatments, in the hope that they might lessen the side 
effects of treatment, improve quality of life, give them a 
greater sense of control, and reduce stress.4–8 Surveys in the 
UK, Australia, and the US have shown that 10%–49% of the 
general population have used at least one form of CAM.9,10 
CAM use appears to be even higher in Singapore, where a 
recent survey found that 76% of the population had used at 
least one form of CAM over a 12-month period.11 A number 
of surveys have found that the use of CAM as an adjuvant 
to cancer treatment is more frequent among breast cancer 
patients (63%–87%) than among other cancer patients.4,12–14 
In light of the fashionable use of CAM in the public arena, 
the American Hospital Association undertook a recent survey 
which showed that about 72% of hospitals in metropolitan 
regions are offering CAM.15
Recent studies have found that more than 80% of cancer 
patients reported having used CAM, and that 75% of these 
patients did not tell their doctors that they were doing so.16,17 
Dietary supplements (DS), such as herbs and vitamins, are the 
most popular choices of CAM among cancer patients.4,18–20 
According to the US Food and Drug Administration (FDA), 
a dietary supplement is defined as follows:
A product taken by mouth that contains a “dietary 
ingredient” intended to supplement the diet. The “dietary 
ingredients” in these products may include: vitamins, 
  minerals, herbs or other botanicals, amino acids, and 
substances such as enzymes, organ tissues, glandular, and 
metabolites … also extracts or concentrates, and may be 
found in many forms such as tablets, capsules, soft gels, 
gel caps, liquids, or powders.21
Under the Dietary Supplement Health and Education Act 
(DSHEA) of 1994, dietary supplements are regulated in the 
US as foods, not drugs. Unlike pharmaceutical companies, 
DS manufacturers are not required to prove the safety or 
effectiveness of their products, and the FDA can take action 
only after a DS has been proven to be harmful.22 Many coun-
tries, including Hong Kong, take the reference of the DSHEA 
for regulating DS. Therefore, some patients may consider a 
DS as a type of food which need not be taken into account 
in a detailed drug history. This may be a dangerous assump-
tion. A pharmacologic study has shown that a high dose of 
vitamin C, an antioxidant, can interfere with radiotherapy, 
while some herbs may increase the risk of bleeding during 
surgery.23 However, very few breast cancer patients who use 
DS seem to be aware that there may be risks associated with 
use of such preparations. Because the use of DS is so wide-
spread among breast cancer patients, there is an urgent need 
to study how patients use such supplements and how they 
regard them, so that communication between health profes-
sionals and patient educators and patients can be improved, 
and patients can be properly informed of the benefits and 
risks involved in the use of DS. Thus, this pilot study was 
undertaken to assess the level of usage of DS by breast cancer 
patients undergoing conventional cancer   treatment and their 
concerns about the use of DS.
To obtain this information, this survey investigated: 
characteristics of DS users; patterns of utilization of DS, 
including the commencement of DS; types of DS used and 
associated costs; reasons why subjects used them; whether 
subjects disclosed their use of DS to clinicians, and their 
reasons for disclosure or nondisclosure; and whether subjects 
had concerns about their use of DS, including adverse events, 
and if so, the nature of these concerns.
Methods
study design and population
The study took the form of a cross-sectional descriptive 
  survey. A convenience sampling of 100 breast cancer women 
from cancer centers of a university-affiliated hospital, a 
  government hospital, and a private clinic in Hong Kong, 
would be invited for the study after written informed consent 
was obtained during their routine oncology follow-up in 
2002. Strict inclusion criteria were adopted. The participants 
had to be female Cantonese speakers without cognitive or 
physical impairments, at least 30 years old, diagnosed with 
Stage I–III breast cancer according to the International 
Union Against Cancer TNM Classification of Malignant 
Tumors and the American Joint Committee on Cancer 
stage grouping,24 who had cancer in only one breast and no 
cancer metastases, and who had completed an anticancer 
treatment (eg, surgery, chemotherapy, radiotherapy) in the 
previous three years, and were not receiving any concurrent 
medical treatment.
Questionnaire
Individual face-to-face interviews using a semistructured 
questionnaire were designed to assess the response to DS use 
among breast cancer patients. The interview questionnaire 
was developed from an indepth literature review and expert 
panel review (two physicians and one nurse). The question-
naire was also tested for understanding in 10 patients. The 
questionnaire sought demographic information, patterns 
of DS use, including commencement of using DS, type, 
frequency, and cost of using DS in the past three months, 
reasons for using a DS, willingness to disclose DS use to Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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oncologists or nurses, and concerns about adverse events 
from using DS. Demographics, including age, gender, 
education, occupation, religion, marital status, country 
of birth, area of residence, and duration of living in Hong 
Kong were obtained to   supplement existing information 
on the respondents’ health status. The interviews lasted 
approximately 20 minutes and were conducted by trained 
interviewers.
Data collection
Informed written consent was obtained from the subjects 
during a routine oncology follow-up, and face-to-face 
interviews were then arranged with each subject. Subjects 
were telephoned the day before the interview and requested 
to write down any type of DS they had used in the previ-
ous three months, including Western supplements, herbal 
tea (ingredients), herbal soup (ingredients), and Chinese 
proprietary medicinal supplements, and to state how much 
they had spent on such supplements. A period of only three 
months was used as the reference in order to minimize 
recall bias. During the interview, the subjects were first 
asked whether they had ever used DS during conventional 
cancer treatment, and if so, which types of DS they had 
been using in the previous three months and what their 
ingredients were, how often they used them, and how much 
(in Hong Kong dollars) they spent each month on them. 
They were also asked why they used DS and whether any 
adverse events had occurred while they were taking them. 
Finally, they were asked how they had learned about DS, 
and whether they disclosed their use of DS to their oncolo-
gist or nurse.
statistical analyses
All data management and analyses were performed using 
SPSS (version13.0; SPSS Inc, Chicago, IL) Types, preva-
lence, and patients’ reasons for DS use, attitude towards 
disclosing DS use to oncologists or nurses, and concerns 
about using DS, were described in percentage terms. The 
descriptive statistics were generated first, and the associa-
tions between independent and dependent variables were then 
evaluated. Monthly expenditure on each type of supplement 
was calculated. In extrapolating expenditure on DS, the sur-
vey data were based on monthly expenditure by the individual 
patient, not her household. The Chi-square test or Fisher’s 
exact test was applied to estimate the association between 
the demographic and   clinical characteristics of patients and 
their DS utilization. The significance level for all analyses 
was set at alpha 0.05, and all tests were two-sided.
ethical considerations
The study was approved by the institutional review board of 
the university involved in the study. All potential participants 
were informed of the details and significance of the study 
and written consent was obtained before the interview. All 
participants were given the opportunity to withdraw from the 
study at any point and were assured that interviewers were 
independent of the services and that the interviews would 
be confidential.
Results
response rate and characteristics  
of sample
Of the 100 breast cancer patients invited to take part in the 
survey, 82 completed the face-to-face interviews between 
June and October 2002, ie, a response rate of 82%. The 18 
breast cancer patients who declined to participate in the study 
said either that they did not have time or that they were not 
willing to discuss any issue related to cancer. Characteristics 
of the 82 breast cancer subjects are shown in Table 1. The 
mean age of the participants was 45.8 ± 6.9 years and the 
mean time from the initial diagnosis of cancer to the survey 
was 56.1 ± 28.3 weeks. Most of the subjects had either 
  secondary or higher education (56%), were married (84%), 
were housewives (66%), and held some sort of religious 
belief (60%). Over half were born in Hong Kong (59%), and 
had lived in Hong Kong for 35.5 ± 15.2 years.
characteristics of Ds users
The demographics of the 81 DS users and one nonuser were 
shown in Table 2. Eighty-one of the 82 breast cancer patients 
(99%) reported that they had been using DS continually since 
their cancer was diagnosed.
Pattern of Ds use
Eighty-one (99%) of the 82 breast cancer patients who 
participated in the study reported that they had been using 
DS continually since their cancer was diagnosed. Twenty-
one patients (26%) regularly took at least two types of 
DS. Table 3 shows that all of the 81 subjects taking DS 
used Chinese supplements. Fourteen of these subjects 
(17%) also took Western supplements, and 12 (15%) took 
supplements “extracted from other plants or animals”. The 
most common Chinese supplement was herbal tea, taken 
by 53 subjects (65%), herbal soup, taken by 48 subjects 
(59%), and Chinese proprietary medicine, taken by 42 sub-
jects (52%). Table 4 shows that the most common herbal 
tea ingredient, used by 29/53 subjects (55%), was bai hua Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Table 1 Demographic and clinical characteristics of 82 breast 
cancer patients between June and October 2002 in hong Kong
Mean (SD ) Median (range)
Age (years) 45.8 (6.9) 45.0 (30–63)
Duration in  
hong Kong (years)
35.5 (15.2) 40.0 (1–59)
interval between  
cancer diagnosis and 
survey (weeks)
56.1 (28.3) 52.0 (8–140)
Category Frequency (%)
sex Female 82 (100%)
education #Primary 17 (20.7%)
Form 3 19 (23.2%)
Form 5/vocational/ 
technical/
28 (34.1%)
matriculation level 3 (3.7%)
university/diploma/ 
postgraduate
15 (18.3%)
Occupation health professional 3 (3.7%)
executive/nonhealth 
professional
5 (6.1%)
White collar 13 (15.9%)
Blue collar 7 (8.5%)
housewife/ 
unemployed
54 (65.8%)
religion no religious belief 33 (40.2%)
christianity 17 (20.7%)
Buddhism 13 (15.9%)
Ancestor 2 (2.4%)
Multireligion 17 (20.7%)
Marital status single 8 (9.8%)
Married 69 (84.1%)
Divorced 4 (4.9%)
Widowed 1 (1.2%)
Location of birth hong Kong 48 (58.5%)
Mainland china 31 (37.8%)
Other Asian countries 3 (3.7%)
Location of residence hong Kong island 8 (9.8%)
Kowloon 24 (29.3%)
new Territories 50 (61%)
cancer status stage i 24 (29.3%)
stage ii 51 (62.2%)
stage iii 7(8.5%)
cancer treatment surgery 82 (100%)
chemotherapy 64 (78%)
radiotherapy 61 (74.4%)
hormone replacement 
therapy
58 (70.7%)
Table 2 Demographic characteristics of dietary supplement used 
by breast cancer patients
Category Use of supplement
Yes  
(n = 81)
No  
(n = 1)
Age (years) Mean (sD) 45.9 (6.9) 39 (n.a.)
Duration in  
hong Kong 
(years)
Mean (sD) 35.7 (15.3) 21 (n.a.)
Interval from cancer diagnosis to survey (weeks)
Mean (sD) 56.6 (28.2) 20 (n.a.)
education #Primary level 36 (100%) 0 (0%)
$secondary level 45 (97.8) 1 (2.2%)
Occupation Working class 27 (96.4%) 1 (3.6%)
housewife/ 
retired/ 
unemployed
54 (100%) 0 (0%)
religion no religious  
belief
33 (100%) 0 (0%)
have religious  
belief
48 (98%) 1 (2%)
Marital  
status
single
Married
8 (100%)
73 (98.6%)
0 (0%)
1 (1.4%)
Location  
of birth
hong Kong
Other countries
48 (100%)
33 (97.1%)
0 (0%)
1 (2.9%)
Location of  
residence
not new  
Territories
new Territories
31 (96.9%)
50 (100%)
1 (3.1%)
0 (0%)
cancer status stage i 23 (95.8%) 1 (4.2%)
stage ii 51 (100%) 0 (0%)
stage iii 7 (100%) 0 (0%)
cancer  
treatment
surgery               Yes
no
81 (98.8%)
0 (0%)
1 (1.2%)
0 (0%)
chemotherapy        Yes 63 (98.4%) 1 (1.6%)
no 18 (100%) 0 (0%)
radiotherapy            Yes 61 (100%) 0 (0%)
no 20 (95.2%) 1 (4.8%)
hormone  
replacement  
therapy
Yes 
no
58 (100%) 
23 (95.8%)
0 (0%) 
1 (4.2%)
Abbreviations: sD, standard deviation; n.a, not available.
she cao (Oldenlandia diffusa). The most common herbal 
soup ingredient, used by 29/48 subjects (60%), was huai 
shan (Rhizome dioscoreae), and the most common   Chinese 
  proprietary medicine, used by 25/42 subjects (60%), was 
yun zhi (Coriolus). Only 21% of the subjects using a 
  Chinese supplement consulted a Chinese medical practitio-
ner before taking the supplement. Of the 14 subjects (17%) 
who took Western medicinal supplements, 12 (86%) took 
vitamins. Of the 12 subjects (15%) who took supplements 
“extracted from other plants or animals”, four (33%) took 
shark extract.
The subjects’ knowledge of these various DS came 
from a number of sources. Most (60%) learned about them 
from friends or family members, while 21% were told 
about them by a Chinese medical practitioner and 19% 
learned about them through the media or from seminars. 
Table 5 shows that expenditure on DS by breast cancer sub-
jects was US$257.8 ± 2.6 per month. On average, they spent 
US$2.6 ± 9.5 on Western DS, US$250 ± 257.8 on Chinese 
DS, and US$5.2 ± 17.7 on other types of DS.Patient Preference and Adherence 2010:4
Table 3 Classification and frequency of dietary supplement used 
in 82 breast cancer patients
Frequency (%)
Dietary supplement
  no 1 (1.2%)
  Yes 81 (98.8)
    Western supplement 14 (17.3%)
    chinese supplement 81 (100%)
      herbal tea 53 (65.4%)
      herbal soup 48 (59.3%)
      Proprietary medicine 42 (51.9%)
    Other plant/animal supplements 12 (14.8%)
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Table 4 Top five dietary supplement ingredients used in 81 breast 
cancer patients
Type of dietary supplement  
and ingredients
Frequency Percent
Western supplement  
ingredients (14 users)*
  Any vitamins 12 86
  calcium supplement 6 43
  glucosine sulphate 1 7
  Omega3 1 7
herbal tea ingredients  
(53 users)
  Hedyotis diffusa 29 55
  Herba scutellariae barbatae 24 45
  Ganoderma lucidum 14 26
  Spica prunellae 8 15
    Flos lonicerae japonicae and  
Flos chrysanthemi
7 13
herbal soup ingredients  
(48 users)
  Rhizoma dioscoreae 29 60
  Semen euryales 20 42
  Fructus lycii 16 33
  Arillus longan 12 25
  Semen nelumbinis 11 23
chinese proprietary medicine  
(42 users)
  Coriolus vesicolor 25 60
  Ganoderma lucidum 16 38
  Radix isatidis 1 2
  Radix et Rhizoma ginseng 1 2
  Pteria margaritifera 1 2
    Other plants/animals extraction  
supplements (12 users)
  shark extraction 4 33
  Fish oil extraction 3 25
  Bird nest extraction 1 8
  green tea extraction 1 8
  grape seed extraction 1 8
Note: *Only 4 types of western supplements reported in 81 breast cancer patients.
reasons for and expectations of Ds use
In Table 6, the main reasons given by the 81 breast cancer 
patients who used DS as an adjuvant to conventional cancer 
treatment were that these supplements would “enhance recov-
ery from cancer” (47%), “prevent cancer recurrence” (31%), 
or “boost the immune system” (26%). Others expected that the 
DS would lessen the side effects associated with   chemotherapy 
(14%) and hormone replacement therapy (5%).
Seven (9%) of the 81 breast cancer subjects who took 
DS experienced adverse events which might have been 
related to these supplements, including diarrhea (n = 3), 
itchy skin (n = 2), and stomach discomfort (n = 2). None of 
the subjects who experienced such adverse events consulted 
either a Chinese medical practitioner or a physician or nurse. 
They merely stopped taking the DS until the symptoms 
disappeared.
reasons for disclosure of Ds use  
to clinicians
Only three (4%) of the 81 subjects who took DS said that 
they had been asked by an oncologist or a nurse whether 
they were taking DS, and the single subject who did not take 
DS was not asked either. Sixty of the 81 subjects (74%) did 
not inform their oncologists that they were using DS during 
follow-up. Most of them (95%) said that the reason they did 
not confide in their doctors or nurses was they believed that 
doctors and nurses did not care about DS, did not ask them 
whether they used them, did not approve of DS, and/or did 
not know much about them. Two subjects (3%) believed that 
DS counted as food, and could therefore be taken safely and 
without any prejudice to the conventional cancer treatment 
they were receiving. Twenty-one subjects (26%) consulted 
Chinese medical practitioners, instead of their oncologist or 
nurse, because they believed that Chinese medicine could 
provide holistic care.
Twenty-one subjects (26%) disclosed to their oncologist 
during conventional cancer management that they were 
using DS, because they believed that the physicians should 
have complete knowledge of their CAM practice to avoid 
any possibility of adverse drug interaction.
concerns about using Ds
Sixty-six breast cancer patients (81%) wanted stricter   government 
regulation of Chinese proprietary medicine. Their concerns 
included clinical trial safety (89%),   possible side effects (84%), 
clinical trial efficacy (76%), exact and complete herbal constitu-
ent lists (79%), stringent DS   licensing (62%), and authentication 
of the herbs (24%). Forty-six patients (56%) said that the gov-
ernment should make   information on DS readily available to 
consumers through some sort of public enquiry system.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Discussion
A number of studies have reported that better educated 
female breast cancer patients are more likely to use DS.8,14,25 
The relationship between age and DS use is inconsistent. 
Studies by Boon et al and Velicer and Ulrich have reported 
that older women (ie, women aged 40–64 years) are more 
likely to use DS.14,18 Other studies, however, suggest 
precisely the opposite.5,14,25,26 Some studies have also sug-
gested that patients receiving chemotherapy, either because 
their cancer was more advanced or because they were 
under greater stress, were more likely to use DS to relieve 
stress.7,12,25,27   Demographic and clinical conditions were 
not significantly different between DS users and the single 
nonuser in this study. It might be argued that this sample is 
likely to overestimate the use of DS because its participants 
are more likely to be individuals inclined to use DS and 
the use of convenience sampling. In line with a number of 
previous studies, we found no association between DS use 
and marital status, religious beliefs, and length of residence 
in Hong Kong.8,20,25
In this pilot survey of 82 female breast cancer outpatients 
at Hong Kong cancer centers, it was found that the use of DS 
by patients as an adjuvant to conventional cancer treatment 
was almost universal. This extraordinarily high level of use 
is comparable with that reported in Shanghai (85%), but con-
siderably higher than most usage rates reported in the US and 
Western Europe (28%–83%). The high usage rate in Hong 
Kong probably reflects the esteem traditionally accorded 
to herbal remedies in Chinese culture.4,12,13,28 However, less 
than a quarter of patients would disclose their usage of DS. 
It was found that almost all breast cancer patients continu-
ally used DS once their cancer had been diagnosed, and the 
majority of them used at least one DS. Herbs were the most 
popular type of DS, followed by vitamins and shark extract. 
This pattern accords with those reported in the studies by 
Gotay and Dumitriu in the US and Cui et al in Shanghai.28–30 
The average monthly expenditure of US$258 on DS seems 
very high, but there are little data available for comparison. 
It was conservatively estimated that expenditure on DS in 
the US in 2004 was US$14.9 billion,31 but given the cultural 
differences between Americans and Hong Kong Chinese, 
their different interpretations of what might count as a DS, 
and the different sampling method, this figure cannot be 
usefully compared.
Consistent with the findings of studies by Owens, Sollner 
et al, and Sparber et al, patients used DS because they were 
anxious to do everything possible to enhance their recovery 
from cancer treatment, to try to prevent a recurrence of 
cancer, and to try to boost their immune system.7,8,32
Effective communication between patients and their 
health care providers is critical in exploring CAM’s role in 
cancer treatment.33 For many years, the utilization pattern of 
CAM in cancer patients was unclear, largely because physi-
cians never asked their patients whether they were using 
CAM.34 In this study, for example, only few patients reported 
that their oncologists had asked them whether they were 
using DS. Fortunately, other evidence suggests that, in certain 
cases, patients are likely to discuss the use of CAM with their 
physicians. Two studies predating the present study by one or 
two years indicate that almost one half of cancer survivors 
discussed CAM with either their physicians or nurses.18,35 
Although the evidence from these studies is mixed, health 
professionals clearly need to take the initiative in discussing 
DS use with their patients. In this study, it was found that less 
than one-third of the participants informed their physicians 
or nurses that they were using DS, and they did so during 
follow-up rather than at the beginning of their cancer treat-
ment. Most patients said that the reason they did not confide 
in their doctors or nurses was that they believed that Western 
medical doctors and nurses did not care about DS, did not 
Table  6  reason  for  taking  dietary  supplements  in  81  breast 
cancer patients
Reasons Frequency (%)
enhance recovery 38 (47%)
cancer prevention 25 (31%)
enhance immune 21 (26%)
Lessen side effects of chemotherapy 11 (14%)
Lessen side effects of hormone replacement 
therapy
4 (5%)
clear disease root 3 (4%)
remove internal heat and toxin 3 (4%)
general health promotion 3 (4%)
increase survival rate 1 (1%)
Table 5 expenditure on dietary supplement per month (Us$) in 
82 breast cancer patients
Mean (SD) Median (range)
Dietary supplement 257.8 (2.6) 178.8 (0–1679.9)
  Western supplement 2.6 (9.5) 0 (0–59.8)
  chinese supplement 250 (257.8) 178.8 (0–1679.9)
    herbal tea 14.7 (48.7) 0.8 (0–412.8)
    herbal soup 29.7 (100.4) 1.3 (0–717.9)
    Proprietary medicine 67.5 (140.4) 3.2 (0–112.5)
      Traditional chinese medicine 
practitioner consultation
138.1 (166.8) 76.9 (0–717.9)
  Other plants/animals supplements 5.2 (17.7) 0 (0–92.3)Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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ask them whether they used them, did not approve of DS, 
and/or did not know much about them.
Although most participants in this study reported no seri-
ous ill effects from using DS, a few patients experienced sus-
pected adverse events, including mild diarrhea, itchy skin, 
and stomach discomfort, which was believed to be related 
to the known adverse effects of chemotherapy, radiation, 
surgical side effects, and hormone therapy, consistent with 
the findings of other studies.36,37 Most participants believed 
that DS were a kind of food and, therefore, saw no need to 
inform health professionals that they were using them or 
about any possible adverse events. Interestingly, they were 
not so much concerned that DS might interact adversely with 
Western medicine as they were about the effectiveness and 
safety of DS per se. They wanted to know precisely what 
herbs were used, and what measures were taken to ensure 
quality control. There was great interest in obtaining more 
information on DS. Surprisingly, most of the patients who 
used Chinese supplements were told about them by friends 
or family members. Relatively few patients got their infor-
mation by consulting a Chinese medical practitioner. This 
finding is in line with the observation in Henderson and 
Donatelle’s study that most women with breast cancer used 
at least one CAM therapy without the recommendation of 
their doctor.5 Clearly, it would be preferable if patients had 
access to full and accurate information on DS, and this is an 
area where public health authorities, individual physicians, 
and Chinese medical practitioners all have a role to play.
Our study had several limitations. First, due to its small 
sample size, it may not have distinguished between the char-
acteristics of DS users and nonusers. A study with a larger 
sample size should be considered in order to increase the 
generalizability of the findings. Second, information on the 
perceived benefits of using DS was not collected. Thus, future 
qualitative and quantitative studies should consider investigat-
ing the possible benefits reported by DS users, and attempt 
to obtain further information on the effects of DS on conven-
tional cancer therapy and cancer recurrence and survival rates. 
Last, but not least, the study employed self-reported data, 
which may inaccurately reflect actual adverse effects from 
DS. Despite these limitations, the study findings are based on 
a sample from multiple institutions with a high response rate, 
and thus provide useful information about perceived concerns 
resulting from the use of DS by cancer patients.
Conclusion
To our knowledge, this is the first survey to be conducted on 
DS use and attitudes towards it among female breast cancer 
patients in Hong Kong. The almost universal use of DS 
indicates a higher than expected level of interest in such 
supplements, and a widespread willingness to use them. 
Three-quarters of the 81 patients who took DS said that 
they would like detailed and reliable information on DS, 
but most of them felt that they could not discuss this topic 
with their physicians and nurses during oncology follow-up. 
They preferred a nonjudgmental source of information, such 
as a government hotline. Therefore, open communication 
by health professionals, regulation of labeling of DS, and 
patient education about use of DS are required.
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